➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Harvard Business School
Medtronic
Baxter
Boehringer Ingelheim

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020752

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 020752 describes PEPCID RPD, which is a drug marketed by Merck and is included in one NDA. Additional details are available on the PEPCID RPD profile page.

The generic ingredient in PEPCID RPD is famotidine. There are eighteen drug master file entries for this compound. Ninety suppliers are listed for this compound. Additional details are available on the famotidine profile page.
Summary for 020752
Tradename:PEPCID RPD
Applicant:Merck
Ingredient:famotidine
Patents:0
Formulation / Manufacturing:see details
Medical Subject Heading (MeSH) Categories for 020752

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength20MG
Approval Date:May 28, 1998TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength40MG
Approval Date:May 28, 1998TE:RLD:No

Expired US Patents for NDA 020752

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-001 May 28, 1998   Start Trial   Start Trial
Merck PEPCID RPD famotidine TABLET, ORALLY DISINTEGRATING;ORAL 020752-002 May 28, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
AstraZeneca
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.